Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Cash & Equivalents (2020 - 2021)

Historic Cash & Equivalents for Design Therapeutics (DSGN) over the last 2 years, with Q3 2021 value amounting to $357.7 million.

  • Design Therapeutics' Cash & Equivalents changed N/A to $357.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $357.7 million, marking a year-over-year change of. This contributed to the annual value of $2.4 million for FY2020, which is N/A changed from last year.
  • Design Therapeutics' Cash & Equivalents amounted to $357.7 million in Q3 2021.
  • Over the past 5 years, Design Therapeutics' Cash & Equivalents peaked at $400.7 million during Q1 2021, and registered a low of $2.4 million during Q4 2020.